Search

Your search keyword '"Durand‐Zaleski, Isabelle"' showing total 1,151 results
Start Over Author "Durand‐Zaleski, Isabelle"
1,151 results on '"Durand‐Zaleski, Isabelle"'

3. The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective

Author

Lamy, Andre, Eikelboom, John, Tong, Wesley, Yuan, Fei, Bangdiwala, Shrikant I., Bosch, Jackie, Connolly, Stuart, Lonn, Eva, Dagenais, Gilles R., Branch, Kelley R. H., Wang, Wei-Jhih, Bhatt, Deepak L., Probstfield, Jeffrey, Ertl, Georg, Störk, Stefan, Steg, P. Gabriel, Aboyans, Victor, Durand-Zaleski, Isabelle, Ryden, Lars, and Yusuf, Salim

Published
2024
Full Text
View/download PDF

4. Three-Year Outcomes With Fractional Flow Reserve–Guided or Angiography-Guided Multivessel Percutaneous Coronary Intervention for Myocardial Infarction

Author

Puymirat, Etienne, Cayla, Guillaume, Simon, Tabassome, Steg, Philippe Gabriel, Montalescot, Gilles, Durand-Zaleski, Isabelle, Ngaleu Siaha, Fabiola, Gallet, Romain, Khalife, Khalife, Morelle, Jean-François, Motreff, Pascal, Lemesle, Gilles, Dillinger, Jean-Guillaume, Lhermusier, Thibault, Silvain, Johanne, Roule, Vincent, Labèque, Jean-Noel, Rangé, Grégoire, Ducrocq, Grégory, Cottin, Yves, Blanchard, Didier, Charles Nelson, Anaïs, Djadi-Prat, Juliette, Chatellier, Gilles, and Danchin, Nicolas

Published
2024
Full Text
View/download PDF

5. Somatostatin vs. Octreotide for Prevention of Postoperative Pancreatic Fistula The PREFIPS Randomized Clinical Trial A FRENCH 007 – ACHBT Study

Author

Gaujoux, Sébastien, Regimbeau, Jean-Marc, Piessen, Guillaume, Truant, Stéphanie, Foissac, Frantz, Barbier, Louise, Buc, Emmanuel, Adham, Mustapha, Fuks, David, Deguelte, Sophie, Muscari, Fabrice, Sulpice, Laurent, Vaillant, Jean-Christophe, Schwarz, Lilian, Sa Cunha, Antonio, Muzzolini, Milena, Dousset, Bertrand, Sauvanet, Alain, Abdoul, Hendy, Antomarchi, Olivier, Boudon, Marc, Carrere, Nicolas, Cauchy, François, Chebaro, Alexandre, Cherqui, Daniel, Crombe, Thibault, Cuellar, Emmanuel, D’avout, Ariane, de Ponthaud, Charles, Dubois, Clément, Durand-Zaleski, Isabelle, Dokmak, Safi, El Amrani, Mehdi, Gagniere, Johan, Gandon, Anne, Gayet, Brice, Hain, Elisabeth, Jeune, Florence, Kepenekian, Vahan, Leconte, Mahaut, Leroy, Bertrand, M’ba, Lena, Mare, Alexandru, Marques, Frédéric, Massault, Pierre-Philippe, Mensier, Alexandre, Millet, Guillaume, Navez, Julie, Perinel, Julie, Pelascani, Elise, Pezet, Denis, Piardi, Tullio, Pittau, Gabriella, Prodeau, Mathieu, Renard, Yohann, Rousseau, Géraldine, Schneck, Anne-Sophie, Slim, Karem, Suc, Bertrand, Tabchouri, Nicolas, Trechot, Boris, Tribillon, Ecoline, Tubbax, Candice, Tuech, Jean-Jacques, Tzedakis, Stylianos, Veziant, Julie, and Zerbib, Philippe

Published
2024
Full Text
View/download PDF

8. Rationale and design of the FRENch CoHort of myocardial Infarction Evaluation (FRENCHIE) study

Author

Gautier, Alexandre, Danchin, Nicolas, Ducrocq, Gregory, Rousseau, Alexandra, Cottin, Yves, Cayla, Guillaume, Prunier, Fabrice, Durand-Zaleski, Isabelle, Ravaud, Philippe, Angoulvant, Denis, Coste, Pierre, Lemesle, Gilles, Bouleti, Claire, Popovic, Batric, Ferrari, Emile, Silvain, Johanne, Dubreuil, Olivier, Lhermusier, Thibault, Goube, Pascal, Schiele, François, Vanzetto, Gérald, Aboyans, Victor, Gallet, Romain, Eltchaninoff, Hélène, Thuaire, Christophe, Dillinger, Jean-Guillaume, Paganelli, Franck, Gourmelen, Julie, Steg, Philippe Gabriel, and Simon, Tabassome

Published
2024
Full Text
View/download PDF

12. Photocoagulation or sham laser in addition to conventional anti-VEGF therapy in macular edema associated with TelCaps due to diabetic macular edema or retinal vein occlusion (TalaDME): a study protocol for a multicentric, French, two-group, non-commercial, active-control, observer-masked, non-inferiority, randomized controlled clinical trial

Author

Dupas, Bénédicte, Castro-Farias, Daniela, Girmens, Jean-François, Eginay, Ali, Couturier, Aude, Villeroy, Frederic, Delyfer, Marie-Noëlle, Creuzot-Garcher, Catherine, Giocanti-Auregan, Audrey, Béral, Laurence, Arndt, Carl, Mesnard, Charles, Vicaut, Eric, Chaumet-Riffaud, Philippe, Durand-Zaleski, Isabelle, and Paques, Michel

Published
2024
Full Text
View/download PDF

15. Economic evaluation and budget-impact of accelerated partial breast irradiation (APBI) versus standard or hypofractionated whole breast irradiation (WBI) in postmenopausal women with early-stage breast cancer. Results from the French SHARE randomized trial

Author

Le Bras, Alicia, Belkacemi, Yazid, Bourgier, Celine, Gabelle-Flandin, Isabelle, Petit, Adeline, Guilbert, Philippe, Geffrelot, Julien, Racadot, Severine, Rivin Del Campo, Eleonor, Hanzen, Chantal, Charra Brunaud, Claire, Auzac, Guillaume, Lacornerie, Thomas, Lemonnier, Jerome, Lartigau, Eric, and Durand-Zaleski, Isabelle

Published
2023
Full Text
View/download PDF

16. Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial

Author

Pellerin, Olivier, Sabatier, Brigitte, Dariane, Charles, Gabay, Benjamin, Moldovan, Paul Cezar, Rouvière, Olivier, Champagnac, Jean, Lagabrielle, Samuel, Grenier, Nicolas, Boissier, Romain, Lechevallier, Éric, Izaaryene, Jalal-Jean, Tradi, Farouk, Arrouasse, Raphaele, Defontaines, Julien, Joseph, Xavier, Le Corvoisier, Philippe, Sbidian, Emilie, Champy, Cécile, Chiaradia, Mélanie, Chevrot, Armand, Blion, Cyrille, Goupil, Jean, Bulsei, Julie, Vappereau, Alexandra, Sapoval, Marc, Thiounn, Nicolas, Descazeaud, Aurélien, Déan, Carole, Ruffion, Alain, Pagnoux, Gaële, Duarte, Ricardo Codas, Robert, Grégoire, Petitpierre, Francois, Karsenty, Gilles, Vidal, Vincent, Murez, Thibaut, Vernhet-Kovacsik, Hélène, de la Taille, Alexandre, Kobeiter, Hicham, Mathieu, Romain, Heautot, Jean-Francois, Droupy, Stéphane, Frandon, Julien, Barry Delongchamps, Nicolas, Korb-Savoldelli, Virginie, Durand-Zaleski, Isabelle, Pereira, Helena, and Chatellier, Gilles

Published
2023
Full Text
View/download PDF

20. Improving economic evaluations in stroke: A report from the ESO Health Economics Working Group

Author

Cadilhac, Dominique A, Kim, Joosup, Wilson, Alastair, Berge, Eivind, Patel, Anita, Ali, Myzoon, Saver, Jeffrey, Christensen, Hanne, Cuche, Matthieu, Crews, Sean, Wu, Olivia, Provoyeur, Marine, McMeekin, Peter, Durand-Zaleski, Isabelle, Ford, Gary A, Muhlemann, Natalia, Bath, Philip M, Abdul-Rahim, Azmil H, Sunnerhagen, Katharina, Meretoja, Atte, Thijs, Vincent, Weimar, Christian, Massaro, Ayrton, Ranta, Annemarei, and Lees, Kennedy R

Subjects
Health Services and Systems, Health Sciences, Clinical Research, Stroke, Good Health and Well Being, economic evaluation, health policy, health outcomes, modified Rankin Scale, EuroQol, ESO Health Economics Working group, Cardiovascular medicine and haematology, Epidemiology, Public health
Abstract

IntroductionApproaches to economic evaluations of stroke therapies are varied and inconsistently described. An objective of the European Stroke Organisation (ESO) Health Economics Working Group is to standardise and improve the economic evaluations of interventions for stroke.MethodsThe ESO Health Economics Working Group and additional experts were contacted to develop a protocol and a guidance document for data collection for economic evaluations of stroke therapies. A modified Delphi approach, including a survey and consensus processes, was used to agree on content. We also asked the participants about resources that could be shared to improve economic evaluations of interventions for stroke.ResultsOf 28 experts invited, 16 (57%) completed the initial survey, with representation from universities, government, and industry. More than half of the survey respondents endorsed 13 specific items to include in a standard resource use questionnaire. Preferred functional/quality of life outcome measures to use for economic evaluations were the modified Rankin Scale (14 respondents, 88%) and the EQ-5D instrument (11 respondents, 69%). Of the 12 respondents who had access to data used in economic evaluations, 10 (83%) indicated a willingness to share data. A protocol template and a guidance document for data collection were developed and are presented in this article.ConclusionThe protocol template and guidance document for data collection will support a more standardised and transparent approach for economic evaluations of stroke care.

Published
2020

21. Multicentre medicoeconomic evaluation of cardiac magnetic resonance imaging for predicting coronary artery disease in left ventricular dysfunction: The CAMAREC study design

Author

Desroche, Louis-Marie, Mandry, Damien, Ducrocq, Gregory, Durand-Zaleski, Isabelle, Alfaiate, Toni, Millischer, Damien, Milleron, Olivier, Huttin, Olivier, Valla, Mathieu, Belle, Loic, Lavie-Badie, Yoan, Farah, Bruno, Diakov, Christelle, Logeart, Damien, Safar, Benjamin, Burdet, Charles, and Jondeau, Guillaume

Published
2023
Full Text
View/download PDF

22. Données et preuves en vie réelle dans l’évaluation des technologies de santé : dans quels cas sont-elles complémentaires, substitutives, ou les seules sources de données par rapport aux essais cliniques ?

Author

de Pouvourville, Gérard, Armoiry, Xavier, Lavorel, Aurélie, Bilbault, Pascal, Maugendre, Philippe, Bensimon, Lionel, Beziz, Dan, Blin, Patrick, Borget, Isabelle, Bouée, Stéphane, Collignon, Cécile, Dervaux, Benoît, Durand-Zaleski, Isabelle, Julien, Marc, de Léotoing, Lucie, Majed, Laureen, Martelli, Nicolas, Séjourné, Thomas, and Viprey, Marie

Published
2023
Full Text
View/download PDF

28. Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany

Author

Griesinger, Frank, Pérol, Maurice, Girard, Nicolas, Durand-Zaleski, Isabelle, Zacharias, Stefan, Bosquet, Lise, Jänicke, Martina, Quantin, Xavier, Groth, Annika, Fleitz, Annette, Calleja, Alan, Patel, Sonya, Lacoin, Laure, Daumont, Melinda J., Penrod, John R., Carroll, Robert, Waldenberger, Daniela, Reynaud, Dorothée, Thomas, Michael, and Chouaid, Christos

Published
2022
Full Text
View/download PDF

31. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis

Author

Nahon, Pierre, Asselah, Tarik, Guyader, Dominique, Pol, Stanislas, Fontaine, Hélène, Pageaux, Georges-Philippe, De Lédinghen, Victor, Ouzan, Denis, Zoulim, Fabien, Roulot, Dominique, Tran, Albert, Bronowicki, Jean-Pierre, Decaensi, Thomas, Riachi, Ghassan, Calès, Paul, Péron, Jean-Marie, Alric, Laurent, Bourlière, Marc, Mathurin, Philippe, Dharancy, Sebastien, Blanc, Jean-Frédéric, Abergel, Armand, Chazouillères, Olivier, Mallat, Ariane, Grangé, Jean-Didier, Attali, Pierre, d’Alteroche, Louis, Wartelle, Claire, Dao, Thông, Thabut, Dominique, Pilette, Christophe, Silvain, Christine, Christidis, Christos, Nguyen-Khac, Eric, Bernard-Chabert, Brigitte, Hillaire, Sophie, Di Martino, Vincent, Bonnet, Delphine, Payssan-Sicart, Virginie, Pomes, Chloe, Bailly, François, Beaudoin, Marjolaine, Giboz, Dominique, Hartig-Lavie, Kerstin, Maynard, Marianne, Billaud, Eric, Boutoille, David, Cavellec, Morane, Cheraud-Carpentier, Marjorie, Hubert, Isabelle, Benhida, Jaouad, Lannes, Adrien, Lunel, Françoise, Oberti, Frédéric, Boyer, Nathalie, Giuily, Nathalie, Castelnau, Corinne, Scoazec, Giovanna, Chibah, Aziza, Keser, Sylvie, Bonardi, Karim, Vallet-Pichard, Anaïs, Sogni, Philippe, Foucher, Juliette, Hiriart, Jean-Baptiste, Wilson, Amy, Shili, Sarah, Chermak, Faiza, Ansaldi, Christelle, Ben Amara, Nisserine, Chouquet, Laëtitia, De Luca, Emilie, Oules, Valérie, Anty, Rodolphe, Gelsi, Eve, Truchi, Régine, Luckina, Elena, Messaoudi, Nadia, Moussali, Joseph, De Dieuleveult, Barbara, Labarriere, Damien, Poter, Pascal, Si Ahmed, Si Nafa, Grando-Lemaire, Véronique, Bourcier, Valérie, Brulé, Séverine, Stalhberger, Thomas, Jezequel, Caroline, Brener, Audrey, Laligant, Anne, Rabot, Aline, Renard, Isabelle, Baumert, Thomas F., Dofföel, Michel, Mutter, Catherine, Simo-Noumbissie, Pauline, Razi, Esma, Barraud, Hélène, Bensenane, Mouni, Nani, Abdelbasset, Hassani-Nani, Sarah, Bernard, Marie-Albertine, Bismuth, Michael, Caillo, Ludovic, Faure, Stéphanie, Ripault, Marie Pierre, Bureau, Christophe, Peron, Jean Marie, Robic, Marie Angèle, Tarallo, Léa, Faure, Marine, Froissart, Bruno, Hilleret, Marie-Noelle, Zarski, Jean-Pierre, Goria, Odile, Grard, Victorien, Montialoux, Hélène, François, Muriel, Ouedraogo, Christian, Pauleau, Christelle, Varault, Anne, Andreani, Tony, Angoulevant, Bénédicte, Chevance, Azeline, Serfaty, Lawrence, Antonini, Teresa, Coilly, Audrey, Duclos Vallée, Jean-Charles, Tateo, Mariagrazia, Bonny, Corinne, Brigitte, Chanteranne, Lamblin, Géraldine, Muti, Léon, Babouri, Abdenour, Filipe, Virginie, Barrault, Camille, Costes, Laurent, Hagège, Hervé, Merbah, Soraya, Carrier, Paul, Debette-Gratien, Maryline, Jacques, Jérémie, Lassailly, Guillaume, Artu, Florent, Canva, Valérie, Dharancy, Sébastien, Louvet, Alexandre, Latournerie, Marianne, Bardou, Marc, Mouillot, Thomas, Bacq, Yannick, Barbereau, Didier, Nicolas, Charlotte, Chevalier, Caroline, Archambeaud, Isabelle, Habes, Sarah, Botta-Fridlund, Danièle, Saillard, Eric, Lafrance, Marie-Josée, Cacoub, Patrice, Carrat, Fabrice, Carrieri, Patrizia, Delarocque-Astagneau, Elisabeth, De Ledinghen, Victor, Dorival, Céline, Dubuisson, Jean, Housset, Chantal, Larrey, Dominique, Marcellin, Patrick, Pawlotsky, Jean-Michel, Petrov-Sanchez, Ventzislava, Vaux, Sophie, Wittkop, Linda, Yazdanpanah, Yazdan, Zucman-Rossi, Jessica, Ganne-Carrié, Nathalie, Chaffaut, Cendrine, Moreno, Christophe, Moirand, Romain, Carbonell, Nicolas, Duclos-Vallée, Jean-Charles, de Ledinghen, Victor, Ozenne, Violaine, Henrion, Jean, Perlemuter, Gabriel, Amiot, Xavier, Chevret, Sylvie, Najean, Marie, Layese, Richard, Zarca, Kevin, Segar, Laeticia Blampain, Cagnot, Carole, N’Kontchou, Gisèle, Ronot, Maxime, Audureau, Etienne, and Durand-Zaleski, Isabelle

Published
2022
Full Text
View/download PDF

32. Real-world data and evidence in health technology assessment: When are they complementary, substitutes, or the only sources of data compared to clinical trials?

Author

de Pouvourville, Gérard, Armoiry, Xavier, Lavorel, Aurélie, Bilbault, Pascal, Maugendre, Philippe, Bensimon, Lionel, Beziz, Dan, Blin, Patrick, Borget, Isabelle, Bouée, Stéphane, Collignon, Cécile, Dervaux, Benoît, Durand-Zaleski, Isabelle, Julien, Marc, de Léotoing, Lucie, Majed, Laureen, Martelli, Nicolas, Séjourné, Thomas, and Viprey, Marie

Published
2022
Full Text
View/download PDF

33. Place des mesures rapportées par les patients (PROMS/PREMS) dans l’évaluation et la valorisation des technologies de santé en France

Author

Roussel, Christophe, Chassany, Olivier, Durand-Zaleski, Isabelle, Josseran, Anne, Alter, Lise, Auquier, Pascal, Bourguignon, Sandrine, Cachoux, Joude, Desforges, Claire, Fernandez, Judith, Gaudin, Anne-Françoise, Germe, Anne-Françoise, Haenel, Estelle, Olivier, Patrick, Maillard, Nicolas, Naïditch, Nicolas, Nguyen, Thao, Péan, Clarisse, Rumeau-Pichon, Catherine, Sales, Jean-Patrick, Schmidely, Nathalie, Tuppin, Philippe, and Vray, Muriel

Published
2022
Full Text
View/download PDF

34. Place of patient-reported outcomes & experiences measurements (PROMS/PREMS) in the assessment and pricing of Health technologies in France

Author

Roussel, Christophe, Chassany, Olivier, Durand-Zaleski, Isabelle, Josseran, Anne, Alter, Lise, Auquier, Pascal, Bourguignon, Sandrine, Cachoux, Joude, Desforges, Claire, Fernandez, Judith, Gaudin, Anne-Françoise, Germe, Anne-Françoise, Haenel, Estelle, Olivier, Patrick, Maillard, Nicolas, Naïditch, Nicolas, Nguyen, Thao, Péan, Clarisse, Rumeau-Pichon, Catherine, Sales, Jean-Patrick, Schmidely, Nathalie, Tuppin, Philippe, and Vray, Muriel

Published
2022
Full Text
View/download PDF

35. Markov Models for Health Economic Evaluations: The R Package heemod

Author

Filipović-Pierucci, Antoine, Zarca, Kevin, and Durand-Zaleski, Isabelle

Subjects
Statistics - Applications
Abstract

Health economic evaluation studies are widely used in public health to assess health strategies in terms of their cost-effectiveness and inform public policies. We developed an R package for Markov models implementing most of the modelling and reporting features described in reference textbooks and guidelines: deterministic and probabilistic sensitivity analysis, heterogeneity analysis, time dependency on state-time and model-time (semi-Markov and non-homogeneous Markov models), etc. In this paper we illustrate the features of heemod by building and analysing an example Markov model. We then explain the design and the underlying implementation of the package., Comment: 30 pages, 9 figures. To be published in: Journal of Statistical Software, website at https://www.jstatsoft.org

Published
2017

40. Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma

Author

Assenat, Eric, Delhom-Christol, Elisabeth, Guiu, Boris, Ilonca, Alina D., Lonjon, Julie, Pageaux, Georges-Philippe, Abdel-Rehim, Mohamed, Al-laham, Wassim, Bouattour, Mohamed, Castera, Laurent, Dieudonné, Arnaud, Lebtahi, Rachida, Ronot, Maxime, Sibert, Annie, Vilgrain, Valérie, Barraud, Hélène, Bazin, Christophe, Bronowicki, Jean-Pierre, Laurent, Valérie, Mathias, Elodie, Chagneau-Derrode, Carine, Perdrisot, Rémy, Silvain, Christine, Tasu, Jean-Pierre, RenéGerolami, Patrick Borentain, Mundler, Olivier, Seitz, Jean-Francois, Vidal, Vincent, Aubé, Christophe, Bouvier, Antoine, Couturier, Olivier, Oberti, Frédéric, Vervueren, Laurent, Brenot-Rossi, Isabelle, Raoul, Jean-Luc, Sar-ran, Anthony, Chalaye, Julia, Costentin, Charlotte, Itti, Emmanuel, Kobeiter, Hicham, Luciani, Alain, Adam, René, Lewin, Maïté, Samuel, Didier, Edeline, Julien, Garin, Etienne, Rolland, Yan, Archambeaud, Isabelle, Eugene, Thomas, Frampas, Eric, Cassinotto, Christophe, Guyot, Martine, Hiriart, Jean-Baptiste, Lapuyade, Bruno, Vergniol, Julien, Bachellier, Philippe, Detour, Julien, Duclos, Bernard, Greget, Michel, Habersetzer, Francois, Imperiale, Alessio, Merle, Philippe, Rode, Agnès, Morvan, Julie, Nguyen-Khac, Eric, Yzet, Thierry, Baudin, Guillaume, Chevallier, Patrick, Mahamat, Abakar, Piche, Thierry, Razzouk, Micheline, Hillon, Patrick, Loffroy, Romaric, Toubeau, Michel, Vincent, Julie, Barabino, Gabriele, Bouarioua, Nadia, Cuilleron, Muriel, Ecochard, Marie, Prevot-Bitot, Nathalie, Leroy, Vincent, Roux, Julie, Sengel, Christian, Bourcier, Valérie, Carrie, Nathalie Ganne, Seror, Olivier, Costo, Sylvie, Dao, Thông, Pelage, Jean-Pierre, Dumortier, Jérôme, Giammarile, Francesco, Valette, Pierre-Jean, Ghazzar, Nadia, Pellerin, Olivier, Taieb, Julien, Weinmann, Pierre, Berlot, Alexandra Heurgue, Marcus, Claude, Sommacale, Daniele, Castilla-Lièvre, Maria-Angéla, Maitre, Sophie, Marthey, Lysiane, Zarca, Kevin, Mimouni, Maroua, Pereira, Helena, Chatellier, Gilles, and Durand-Zaleski, Isabelle

Published
2021
Full Text
View/download PDF

41. How Should we Use Multicolumn Spinal Cord Stimulation to Optimize Back Pain Spatial Neural Targeting? A Prospective, Multicenter, Randomized, Double-Blind, Controlled Trial (ESTIMET Study)

Author

Rigoard, Philippe, Billot, Maxime, Ingrand, Pierre, Durand-Zaleski, Isabelle, Roulaud, Manuel, Peruzzi, Philippe, Dam Hieu, Phong, Voirin, Jimmy, Raoul, Sylvie, Page, Philippe, Djian, Marie-Christine, Fontaine, Denys, Lantéri-Minet, Michel, Blond, Serge, Buisset, Nadia, Cuny, Emmanuel, Cadenne, Myriam, Caire, François, Ranoux, Danièle, Mertens, Patrick, Naous, Hussein, Simon, Emile, Emery, Evelyne, Béraud, Guillaume, Debiais, Françoise, Durand, Géraldine, Serrie, Alain, Diallo, Bakari, Bulsei, Julie, Ounajim, Amine, Nivole, Kevin, Duranton, Sophie, Naiditch, Nicolas, Monlezun, Olivier, and Bataille, Benoit

Published
2021
Full Text
View/download PDF

44. Efficacy of a tailored PCR-guided triple therapy in the treatment of Helicobacter pylori infection

Author

Baloul, Samia, Barrioz, Thierry, Bizouard, Geoffray, Breuil, Jacques, Buzaglo, Gaelle, Chryssostalis, Ariane, Deforges, Lionel, Doumet, Sylva, Dray, Xavier, Durand-Zaleski, Isabelle, Ghaleh, Bijan, Grattard, Florence, Le Corvoisier, Philippe, Mangeol, Alain, Mion, François, Nahon, Stéphane, Noussair, Latifa, Podglajen, Isabelle, Raskine, Laurent, Roure-Sobas, Chantal, Samaha, Elia, Zerbib, Franck, Delchier, J.-C., Bastuji-Garin, S., Raymond, J., Megraud, F., Amiot, A., Cambau, E., and Burucoa, C.

Published
2020
Full Text
View/download PDF

45. Weight telemonitoring of heart failure versus standard of care in a real‐world setting: Results on mortality and hospitalizations in a 6‐month nationwide matched cohort study.

Author

Roubille, François, Mercier, Grégoire, Lancman, Guila, Pasche, Hélène, Alami, Sarah, Delval, Cécile, Bessou, Antoine, Vadel, Jade, Rey, Amayelle, Duret, Stéphanie, Abraham, Emilie, Chatellier, Gilles, and Durand Zaleski, Isabelle

Subjects
HEART failure, PATIENT selection, COHORT analysis, HOSPITAL care, MEDICAL care costs, MORTALITY
Abstract

Aims: Evaluating the benefit of telemonitoring in heart failure (HF) management in real‐world settings is crucial for optimizing the healthcare pathway. The aim of this study was to assess the association between a 6‐month application of the telemonitoring solution Chronic Care Connect™ (CCC) and mortality, HF hospitalizations, and associated costs compared with standard of care (SOC) in patients with a diagnosis of HF. Methods and results: From February 2018 to March 2020, a retrospective cohort study was conducted using the largest healthcare insurance system claims database in France (Système National des Données de Santé) linked to the CCC telemonitoring database of adult patients with an ICD‐10‐coded diagnosis of HF. Patients from the telemonitoring group were matched with up to two patients from the SOC group based on their high‐dimensional propensity score, without replacement, using the nearest‐neighbour method. A total of 1358 telemonitored patients were matched to 2456 SOC patients. The cohorts consisted of high‐risk patients with median times from last HF hospitalization to index date of 17.0 (interquartile range: 7.0–66.0) days for the telemonitoring group and 27.0 (15.0–70.0) days for the SOC group. After 6 months, telemonitoring was associated with mortality risk reduction (hazard ratio [HR] 0.71, 95% confidence interval [CI] 0.56–0.89), a higher risk of first HF hospitalization (HR 1.81, 95% CI 1.55–2.13), and higher HF healthcare costs (relative cost 1.38, 95% CI 1.26–1.51). Compared with the SOC group, the telemonitoring group experienced a shorter average length of overnight HF hospitalization and fewer emergency visits preceding HF hospitalizations. Conclusion: The results of this nationwide cohort study highlight a valuable role for telemonitoring solutions such as CCC in the management of high‐risk HF patients. However, for telemonitoring solutions based on weight and symptoms, consideration should be given to implement additional methods of assessment to recognize imminent worsening of HF, such as impedance changes, as a way to reduce mortality risk and the need for HF hospitalizations. Further studies are warranted to refine selection of patients who could benefit from a telemonitoring system and to confirm long‐term benefits in high‐risk and stable HF patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during the surveillance of patients with cirrhosis.

Author

Nahon, Pierre, Layese, Richard, Ganne-Carrié, Nathalie, Moins, Cécile, N'Kontchou, Gisèle, Chaffaut, Cendrine, Ronot, Maxime, Audureau, Etienne, Durand-Zaleski, Isabelle, Natella, Pierre-André, Asselah, Tarik, Guyader, Dominique, Pol, Stanislas, Fontaine, Hélène, Pageaux, Georges-Philippe, De Lédinghen, Victor, Ouzan, Denis, Zoulim, Fabien, Roulot, Dominique, and Tran, Albert

Published
2024
Full Text
View/download PDF

47. Evaluation of mechanical thrombectomy in acute ischemic stroke related to a distal arterial occlusion: A randomized controlled trial.

Author

Clarençon, Frédéric, Durand-Zaleski, Isabelle, Premat, Kévin, Baptiste, Amandine, Chabert, Emmanuel, Ferrier, Anna, Labeyrie, Marc-Antoine, Reiner, Peggy, Spelle, Laurent, Denier, Christian, Tuilier, Titien, Hosseini, Hassan, Rodriguez-Régent, Christine, Turc, Guillaume, Fauché, Cédric, Lamy, Matthias, Lapergue, Bertrand, Consoli, Arturo, Barbier, Charlotte, and Boulanger, Marion

Subjects
*ISCHEMIC stroke, *ARTERIAL occlusions, *RANDOMIZED controlled trials, *THROMBECTOMY, *QUALITY-adjusted life years, *THROMBOLYTIC therapy
Abstract

Rationale: Mechanical thrombectomy (MT) associated with the best medical treatment (BMT) has recently shown efficacy for the management of acute ischemic stroke (AIS) secondary to a large vessel occlusion. However, evidence is lacking regarding the benefit of MT for more distal occlusions. Aim: To evaluate the efficacy in terms of good clinical outcome at 3 months of MT associated with the BMT over the BMT alone in AIS related to a distal occlusion. Methods: The DISCOUNT trial is a multicenter open-label randomized controlled trial involving French University hospitals. Adult patients (⩾18 years) with an AIS involving the anterior or posterior circulation secondary to a distal vessel occlusion within 6 h of symptom onset or within 24 h if no hyperintense signal on fluid attenuation inversion recovery acquisition will be randomized 1:1 to receive either MT associated with the BMT (experimental group) or BMT alone (control group). The number of patients to be included is 488. Study outcomes: The primary outcome is the rate of good clinical outcome at 3 months defined as a modified Rankin scale (mRS) ⩽2 and evaluated by an independent assessor blinded to the intervention arm. Secondary outcomes include recanalization of the occluded vessel within 48 h, angiographic reperfusion in the experimental group, 3-month excellent clinical outcome (mRS ⩽ 1), all adverse events, and death. A cost utility analysis will estimate the incremental cost per quality-adjusted life year (QALY) gained. Discussion: If positive, this study will open new insights in the management of AISs. Trial registration: ClinicalTrials.gov: NCT05030142 registered on 1 September 2021. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. 14‐day tailored PCR‐guided triple therapy versus 14‐day non‐Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open‐label randomized noninferiority controlled trial.

Author

Amiot, Aurelien, Hacoon, Jérémy, Heluwaert, Frederic, Mion, François, Lamarque, Dominique, Moussata, Driffa, Mimouni, Maroua, Delchier, Jean‐Charles, Durand‐Zaleski, Isabelle, Audureau, Etienne, Bastuji‐Garin, Sylvie, Kedzia, Cecile, Samia, Baloul, Dalila, Selmane, Amel, Gouja, Petitdidier, Nicolas, Gagniere, Charlotte, Martin, Antoine, Levy, Michael, and Nebbad, Biba

Subjects
HELICOBACTER pylori, HELICOBACTER pylori infections, ESOMEPRAZOLE, CLARITHROMYCIN
Abstract

Background: The systematic use of susceptibility testing and tailored first‐line treatment for Helicobacter pylori eradication has yet to be established. Aim: To compare 14‐day tailored PCR‐guided triple therapy to 14‐day non‐Bismuth concomitant quadruple therapy for first‐line Helicobacter pylori eradication. Patients and Methods: We performed a multicenter, parallel‐group, randomized noninferiority controlled trial. Naive adult patients with Helicobacter pylori infection were treated with 14‐day tailored PCR‐guided triple therapy (esomeprazole 40 mg and amoxicillin 1000 mg b.d. plus clarithromycin 500 mg or levofloxacin 500 mg b.d. according to clarithromycin susceptibility) or 14‐day non‐Bismuth concomitant quadruple therapy (esomeprazole 40 mg, amoxicillin 1000 mg, clarithromycin 500 mg, and metronidazole 500 mg b.d.). The primary endpoint was H. pylori eradication. Results: We screened 991 patients for eligibility and randomized 241 patients. The first‐line eradication rate was 99.2% in the tailored PCR‐guided group and 95.9% in the control group (ITT population; absolute difference of +3.30%, with a lower bound of CI at −0.68%). Both first‐line therapies were well tolerated, with a formally significant difference in favor of the tailored PCR‐guided group (61.4% vs. 41.2%, p = 0.003). Economic analyses revealed a lower cost of the tailored PCR‐guided arm, with a 92% chance of being jointly more effective and less expensive than the control arm in the ITT population. Conclusion: In a country with a high level of clarithromycin resistance, the results of our study demonstrated the noninferiority of 14‐day tailored PCR‐guided triple therapy as a first‐line H. pylori eradication therapy compared to 14‐day non‐Bismuth quadruple therapy (ClinicalTrials.gov NCT02576236). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study

Author

Legendre, Paul, Chahwan, Doumit, Marjanovic, Zora, Vignon, Marguerite, Hermine, Olivier, Lortholary, Olivier, Morelle, Guillaume, Darrodes, Marie, Kahn, Jean-Emmanuel, Ouzegdouh, Maya, Chaibi, Pascal, Montestruc, François, Caumont-Prim, Aurore, Le Jouan, Mélisande, Hassani, Yasmine, Godeau, Bertrand, Durand-Zaleski, Isabelle, and Mouthon, Luc

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results